ViiV Healthcare announces new initiatives to improve access to dolutegravir: licence to the Medicines Patent Pool
ViiV Healthcare today announced new collaborations with the goal of increasing access to its HIV medicine, dolutegravir (marketed under the name Tivicay®), just two months after its approval by the European Medicines Agency (EMA) and eight months after approval by the US Food and Drug Administration (FDA). (Source: GSK news)
Source: GSK news - April 1, 2014 Category: Pharmaceuticals Source Type: news
Results from phase III patient preference study of GSK’s Votrient® (pazopanib) vs. Sutent® (sunitinib) in advanced renal cell carcinoma published in Journal of Clinical Oncology
Data from the first patient preference study in advanced renal cell carcinoma have been published in the Journal of Clinical Oncologyi. (Source: GSK news)
Source: GSK news - April 1, 2014 Category: Pharmaceuticals Source Type: news
Regulatory update: Votrient® (pazopanib) as maintenance therapy for advanced ovarian cancer in the EU
GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that it has withdrawn its application to the European Medicines Agency (EMA) for a variation to the Marketing Authorisation for Votrient® (pazopanib). (Source: GSK news)
Source: GSK news - March 31, 2014 Category: Pharmaceuticals Source Type: news
GSK announces new strategic investments in Africa to increase access to medicines, build capacity and deliver sustainable growth
GSK today announced a series of new investments in sub-Saharan Africa designed to address pressing health needs and contribute to long-term business growth. (Source: GSK news)
Source: GSK news - March 31, 2014 Category: Pharmaceuticals Source Type: news
GSK presents data from Phase III STABILITY study of darapladib in patients with chronic coronary heart disease
GlaxoSmithKline plc (LSE/NYSE: GSK) today presented data from the pivotal Phase III STABILITY study of darapladib at the American College of Cardiology 63rd Annual Scientific Session in Washington, DC (Source: GSK news)
Source: GSK news - March 30, 2014 Category: Pharmaceuticals Source Type: news
GSK acquires full ownership of its Indonesian Consumer Healthcare business
GlaxoSmithKline (GSK) has acquired full ownership of its Indonesian Consumer Healthcare business in a transaction which also includes the company divesting a non-core brand and a manufacturing facility in the country. (Source: GSK news)
Source: GSK news - March 28, 2014 Category: Pharmaceuticals Source Type: news
Where do you start when developing a new medicine?
A pioneering public-private research initiative between GSK, the European Bioinformatics Institute (EMBL-EBI) and the Wellcome Trust Sanger Institute is to harness the power of ‘big data’ and genome sequencing to improve the success rate for discovering new medicines. (Source: GSK news)
Source: GSK news - March 27, 2014 Category: Pharmaceuticals Source Type: news
GSK receives European authorisation for once-weekly type 2 diabetes treatment, Eperzan® (albiglutide)
GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that the European Commission has granted marketing authorisation for its once-weekly diabetes treatment, Eperzan® (albiglutide). (Source: GSK news)
Source: GSK news - March 26, 2014 Category: Pharmaceuticals Source Type: news
Regulatory update: combined use of Mekinist™ (trametinib) and Tafinlar® (dabrafenib) in Europe
GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that it has withdrawn its Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for the use of Mekinist (trametinib) in combination with the previously approved BRAF inhibitor Tafinlar (dabrafenib). (Source: GSK news)
Source: GSK news - March 26, 2014 Category: Pharmaceuticals Source Type: news
GSK publishes historical quarterly restated financial information
As previously announced, for 2014, GlaxoSmithKline (LSE:GSK) will adopt a revised presentation for the analysis of its Pharmaceuticals and Vaccines turnover by segment, product and therapeutic area that identifies revenues from an Established Products Portfolio as a new segment. This new segment comprises a portfolio of over 50 tail brands. (Source: GSK news)
Source: GSK news - March 21, 2014 Category: Pharmaceuticals Source Type: news
Investigational MAGE-A3 antigen-specific cancer immunotherapeutic does not meet first co-primary endpoints in MAGRIT, a phase III non-small cell lung cancer clinical trial
GSK announced that analysis of the MAGRITi trial, a phase III trial of its MAGE-A3 cancer immunotherapeuticii in NSCLC patients, showed that the trial did not meet its first or second co-primary endpoint as it did not significantly extend DFSiii when compared to placebo in either the overall MAGE-A3 positive population or in those MAGE-A3-positive patients who did not receive chemotherapy. (Source: GSK news)
Source: GSK news - March 20, 2014 Category: Pharmaceuticals Source Type: news
GSK and Theravance announce positive results from studies comparing ANORO™ ELLIPTA™ with SERETIDE® DISKUS® and ADVAIR® DISKUS® in patients with COPD
GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced positive results from three phase III studies. (Source: GSK news)
Source: GSK news - March 14, 2014 Category: Pharmaceuticals Source Type: news
Patient recruitment completes in landmark RELVAR®/ BREO® ELLIPTA® Study to Understand Mortality and MorbidITy (SUMMIT) in COPD
GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that recruitment of patients into the “Study to Understand Mortality and MorbidITy”, known as SUMMIT, has completed enrolment. (Source: GSK news)
Source: GSK news - March 13, 2014 Category: Pharmaceuticals Source Type: news
GSK announces positive results from phase III studies for mepolizumab in severe eosinophilic asthma
GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that a pivotal phase III study of mepolizumab, an investigational IL-5 antagonist monoclonal antibody, met its primary endpoint (Source: GSK news)
Source: GSK news - March 12, 2014 Category: Pharmaceuticals Source Type: news
GSK increases stake in Indian Pharmaceuticals subsidiary to 75 per cent after Open Offer
GlaxoSmithKline plc announced today that, following the voluntary Open Offer undertaken by its subsidiary, GlaxoSmithKline Pte Ltd, it has successfully increased its stake in its publicly-listed pharmaceuticals subsidiary in India. (Source: GSK news)
Source: GSK news - March 10, 2014 Category: Pharmaceuticals Source Type: news
